Abstract
Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin, a potent toxin produced by the anaerobic bacterium clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperhidrosis, is used for patients suffering from chronic migraine. In this study, a group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine. The results confirmed the efficacy of onabotulinum toxin A (Botox) when used at the dosage of 155 UI according to the PREEMPT protocol. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of onabotulinum toxin A (Botox) and to assess its use in clinical practice, in particular in migraine field.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483
Dodick D, Turkel C, De Gryse R et al (2010) Onabotulinum toxinA for treatment of chronic migraine: pooled results from double blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936
Diener HC, Dodick D, Aurora S et al (2010) Onabotulinum toxinA for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalagia 30:804–814
Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of onabotulinum toxin A for chronic migraine : a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418
Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274–283
Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793
Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15
Silberstein S, Blumenfeld A, Cady R, Turner I, Lipton R, Diener HC, Aurora S, Sirimanne M, DeGryse R, Turkel C, Dodick D (2013) Onabotulinum toxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 15(331(1–2)):48–56
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808
Ashkenazi A (2010) Botulinum toxin type A for chronic migraine. Curr Neurol Neurosci Rep 10:140–146
Rothrock J, Bloudek LM, Rothrock DA, Varon SF (2014) Real-world economic impact of onabotulinum toxin A in patients with chronic migraine. Headache 54:1565–1573
Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2014) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. doi:10.1177/0333102414561873
Silberstein SD, Dodick WD, Aurora SK, Dienere H-C, DeGryse RE, Lipton RB, Turkel CC (2014) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2013-307149
Conflict of interest
The authors certify that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grazzi, L., Usai, S. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci 36 (Suppl 1), 33–35 (2015). https://doi.org/10.1007/s10072-015-2140-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2140-2